Angiotensin-converting enzyme (ACE) inhibitor; de-esterified in vivo to its active diacid metabolite. Prepn: A. A. Patchett et al., EP 12401; E. E. Harris et al., US 4374829 (1980, 1983 both to Merck & Co.); A. A. Patchett et al., Nature 288, 280 (1980) DOI PubMed. Similtaneous determn with enalaprilat in plasma by HPLC-MS/MS: S. Lu et al., J. Pharm. Biomed. Anal. 49, 163 (2009) DOI PubMed. Comprehensive description: D. P. Ip, G. S. Brenner, Anal. Profiles Drug Subs. 16, 207-243 (1987). Review of pharmacology and clinical experience in congestive heart failure: P. A. Todd, K. L. Goa, Drugs 37, 141-161 (1989) DOI PubMed; in hypertension: eidem, ibid. 43, 346-381 (1992) DOI PubMed. Review of clinical pharmacokinetics: R. J. MacFadyen et al., Clin. Pharmacokinet. 25, 274-282 (1993) DOI PubMed. Review of combination with hydrochlorothiazide: P. L. Malini, Adv. Ther. 10, 253-262 (1993); with lercanidipine: V. Barrios et al., Vasc. Health Risk Manag. 4, 847-853 (2008) PubMed.
Antihypertensive.
ACE-Inhibitor; Antihypertensive; N-Carboxyalkyl (peptide/lactam) Derivatives